AgilVax Progress Triggers $1.2 Million SBIR Fast-Track Grant to Advance Antibody-Based Therapy

On August 18, 2020 AgilVax, Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics to treat multiple types of cancer, reported that the company has triggered Phase II funding worth $1.2 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Cancer Institute (NCI) (Press release, Agilvax, AUG 18, 2020, View Source [SID1234563789]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Targeting redox-sensitive pathways and a protein that is upregulated in tumors that possess NFR2/KEAP1 or KRAS mutations, offers great promise for cancer therapy and AgilVax is poised to establish a new class of treatment for tough to treat cancers."

The funding will be used to conduct a preclinical efficacy study, manufacturing stability studies and a nonclinical toxicology study for AX09, a virus-like-particle (VLP) therapeutic vaccine. AgilVax successfully achieved its goals from the earlier phases allowing the final portion of the grant to be awarded.

AgilVax has three development programs targeting xCT, a cystine-glutamate antiporter: (1) an antibody-drug conjugate (xCT-mAb-ADC), (2), a conjugated radiopharmaceutical and (3) AX09. Oxidative stress leads to enhanced induction of xCT, which regulates cysteine intake, stimulates the conversion of cysteine and subsequent glutathione (GSH) synthesis. xCT expression is low in normal cells but elevated in numerous cancer types corresponding to increases in intracellular reactive oxygen species (ROS). Numerous cancer types are highly resistant to traditional therapies due to oxidative stress induced by cancer cell metabolism.

"We are delighted to receive this grant award from the National Cancer Institute to advance the development of our antibody-based therapeutic program," said Joseph Patti, Ph.D., president and chief executive officer of Agilvax and the Principal Investigator of the award. "Targeting redox-sensitive pathways and a protein that is upregulated in tumors that possess NFR2/KEAP1 or KRAS mutations, offers great promise for cancer therapy and AgilVax is poised to establish a new class of treatment for tough to treat cancers."

National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

On August 18, 2020 MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) reported that Monjuvi (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines) in Oncology for B-cell Lymphomas (Press release, Incyte, AUG 18, 2020, View Source [SID1234563774]). Specifically, the NCCN Guidelines in the United States now include Monjuvi in combination with lenalidomide with a Category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma who are ineligible for autologous stem cell transplant (ASCT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This press release features multimedia. View the full release here: View Source

"We are very gratified the NCCN acted quickly to include Monjuvi in combination with lenalidomide with a Category 2A designation in its Clinical Practice Guidelines in Oncology as a treatment for patients with relapsed or refractory DLBCL who are not candidates for transplant. This targeted therapeutic option helps address an immediate medical need for patients who previously had limited treatment options," said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys. "There is no other FDA-approved second line treatment for these patients with a 2A designation within the NCCN guidelines."

The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide under accelerated approval on July 31, 2020, for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DBLCL arising from low grade lymphoma, and who are not eligible for ASCT. The approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter single arm trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).1

The NCCN is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research and education. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care – including physicians, nurses, pharmacists, payers, patients and their families – with the ultimate goal of improving patient care and outcomes.

"The inclusion of Monjuvi in the NCCN Guidelines will help further inform healthcare providers of this advancement for patients," said Peg Squier, M.D., Group Vice President, U.S. Medical Affairs, Incyte. "We believe Monjuvi has the potential to address an urgent medical need for patients with relapsed or refractory DLBCL and are pleased that the NCCN has acknowledged the clinical benefit of this targeted therapeutic option."

DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide,2 characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with about one in three patients not responding to initial therapy or relapsing thereafter.3 In the United States each year, approximately 10,000 patients are diagnosed with relapsed or refractory DLBCL who are not eligible for ASCT.4,5,6

The updated NCCN Guidelines are available at www.nccn.org.

NCCN and the NCCN Guidelines are registered trademarks of National Comprehensive Cancer Network.

About Monjuvi (tafasitamab-cxix)
Monjuvi is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize Monjuvi globally. Monjuvi will be co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

A marketing authorization application (MAA) seeking the approval of tafasitamab in combination with lenalidomide in the EU has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.

Tafasitamab-cxix is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials.

Monjuvi is a registered trademark of MorphoSys AG.
XmAb is a registered trademark of Xencor, Inc.

Important Safety Information
What are the possible side effects of MONJUVI?
MONJUVI may cause serious side effects, including:

Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get chills, flushing, headache, or shortness of breath during an infusion of MONJUVI.
Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding.
Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or develop any signs and symptoms of an infection.
The most common side effects of MONJUVI include:

Feeling tired or weak
Diarrhea
Cough
Fever
Swelling of lower legs or hands
Respiratory tract infection
Decreased appetite
These are not all the possible side effects of MONJUVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:

Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.
You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.
Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.
Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.
You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

ERC Announces Interim Results from Phase 2 Trial of Immunotherapy ERC1671 in Recurrent Glioblastoma Patients

On August 18, 2020 ERC Belgium, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, reported promising interim results in the phase 2 clinical trial for ERC1671 (also known as Gliovac or SITOIGANAP) under FDA IND 15430 at the University of California, Irvine Medical Center in Orange, California (Press release, ERC Belgium, AUG 18, 2020, View Source [SID1234563790]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial, "ERC1671/GM CSF/Cyclophosphamide+Bevacizumab vs Placebo," is a double-blind, placebo-controlled study of 84 patients with recurrent GBM. Interim unblinding and analysis of the first 10 patients from the study demonstrated the following results in patients treated with ERC1671:

6-month overall survival (OS) rate of 100%;
12-month OS rate of 40%;
Median OS is 46 weeks (10.5 months)
Historic controls have 6-month OS rate of 33% and median OS of 23 weeks (5.3 months). This dataset reveals a striking improvement over current clinical practice and the results demonstrate a highly significant (log rank test, p < 0.0001) increase in the OS of patients when treated with ERC1671.

Approximately 10% of the patients receiving ERC1671 experienced total recovery and survived longer than 3 years when treated following GBM recurrence and after receiving standard of care treatment. In contrast, no spontaneous remissions were observed in the control group and all patients experienced tumor progression.

Furthermore, a subgroup of patients who had failed treatment with bevacizumab (Avastin) benefited disproportionately with an apparent doubling of survival compared to historical controls.

Principal investigator of the clinical trial, Daniela Bota, MD, PhD, commented, "Prior to this study of ERC1671 immunotherapy for recurrent GBM, it was almost unknown for such patients to experience recovery. We are excited to accelerate recruitment and complete this study." Dr. Bota is Vice Dean for Clinical Research, Medical Director, UCI Center for Clinical Research; Director, UCI Alpha Stem Cell Clinic; Medical Director, UCI Health Comprehensive Brain Tumor Program.

Apostolos Stathopoulos, MD, PhD, President and CEO of ERC Worldwide commented, "We are encouraged by such strong results for ERC1671 in Dr. Bota’s study and pleased to see a high number of patients going into remission. We believe that ERC1671 is finally leading the way for immunotherapy to treat intractable cancers like recurrent GBM that currently do not have alternative therapeutic options."

About ERC1671

ERC1671 (Gliovac or SITOIGANAP) is an advanced immunotherapy based on freshly extracted tumor cells and lysates that stimulates the patient’s immune system to recognize and reject cancer cells. The immunotherapy contains a combination of autologous tumor cells, and allogeneic tumor cells, generated from the glioma tumor tissues of three different donor cancer patients, and the lysates of all of these cells. Upon injection, this mixture stimulates the patient’s immune system to mount an immune response against the tumor cells, which may lead to their destruction.

ERC1671 is for patients suffering from a grade IV glioma (glioblastoma multiforme and gliosarcoma) when all other traditional treatments have failed. The response to SITOIGANAP is the same whether the MGMT promoter is methylated or unmethylated.

ERC1671 is currently in randomized, placebo-controlled Phase 2 clinical trials in the United States as part of combination treatment for glioblastoma multiforme and gliosarcoma.

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

On August 18, 2020 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, reported it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020 (Press release, Aeglea BioTherapeutics, AUG 18, 2020, View Source [SID1234563775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Panel Title: Stronger Together: Continuing industry and patient partnerships to ensure inclusion of patient voice along the full continuum of development, from pre-clinical through commercialization
Date/Time: August 24 at 9:10 a.m. EDT
Moderator: Michael C. Hanley, Aeglea’s chief commercial officer

Presentation Title: Next generation human enzymes: Innovative solutions for patients with rare diseases
Date/Time: August 25 at 12:50 p.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer

The company presentation will be available for download on the Presentations & Events section of the Company’s website.

Genosity Receives CLIA Approval for AsTra Profile™ and AsTra Next™ to Enable Earlier Detection of Cancer Relapse Through Patient-Specific Liquid Biopsy Monitoring

On August 18, 2020 Genosity Inc., reported that it has received CLIA approval for its tumor exome and liquid biopsy cancer monitoring platform, AsTra (Assessment and Tracking), designed to identify a patient’s unique tumor molecular profile that can be used for ongoing, personalized Minimal Residual Disease (MRD) monitoring (Press release, Genosity, AUG 18, 2020, View Source [SID1234563792]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Astra testing system enables the assessment and tracking of a patient’s individual and unique tumor genetic signature by employing a multi-step testing strategy. Astra Profile, the first component of the system relies on a comprehensive tumor profile collected through whole exome sequencing on the Illumina NovaSeq 6000 platform to identify each tumor’s unique molecular fingerprint. This fingerprint is then leveraged to generate a patient specific molecular assay using a third-party library prep technology. Astra One, the second component of the system enables detection of the tumors unique signature and initial MRD assessment through non-invasive liquid biopsy. Astra Next, the third component of this platform allows ongoing monitoring and MRD assessment through liquid biopsy as well. The comprehensive platform provides an ability to detect the presence of relapse or residual disease and potentially enable earlier management interventions.

"Next Generation sequencing continues to expand the frontiers of precision medicine. With advances in the Illumina Sequencing technology, we are able to cost effectively leverage a comprehensive Tumor Exome combined with subsequent liquid biopsies to enable truly personalized recurrent and residual disease monitoring" says Dr. Robert Daber, President and CTO of Genosity, Inc. "Working with biopharma and other partners, we are committed to supporting the development of innovative technologies that have the potential to accelerate precision medicine and improve clinical outcomes. The ability to initiate earlier interventions through routine non-invasive testing is disruptive."

Genosity continues to expand its Oncology offerings for research and clinical research applications specifically focused on meeting the needs of the biopharmaceutical community. Genosity is currently working on a variety of innovative pharma projects spanning translational research to late stage clinical trials. Genosity has become an ideal partner for biotech and biopharma companies seeking to advance disruptive genomics technologies due to its synergistic strategic approach of combining the capabilities of a sophisticated central laboratory with its proprietary commercial genomics software solution including a genomics laboratory information management system (LIMS) and reporting platform to assist with distribution and implementation of these research and clinical research assays.